CJC-1295 Powerlifting Strength Training Protocol: Dosing, Timing, and Evidence

What CJC-1295 Is and Why Powerlifters Use It

CJC-1295 is a 30-amino-acid synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs, triggering GH pulse release. The version conjugated to a Drug Affinity Complex (DAC) resists proteolytic cleavage and extends plasma half-life to approximately eight days, allowing twice-weekly dosing rather than daily injections. [1]

Powerlifters do not use CJC-1295 for rapid mass gain. They use it because high-volume, near-maximal loading hammers tendons, ligaments, and articular cartilage at a rate that often exceeds the tissue's natural repair capacity. GH and its downstream mediator IGF-1 directly stimulate collagen synthesis in tendon fibroblasts. A 2019 systematic review in the British Journal of Sports Medicine confirmed that IGF-1 signalling drives tendon collagen turnover and that pharmacological amplification of that signal accelerates repair in animal models. [2]

The Pituitary Mechanism

Endogenous GHRH is secreted in pulses, predominantly during slow-wave sleep. CJC-1295 DAC extends the GH-stimulating signal across multiple natural sleep cycles rather than mimicking a single pulse. This matters for strength athletes: sleep-stage GH release governs roughly 70% of daily GH secretion, and total GH output correlates with connective-tissue anabolism independent of skeletal-muscle protein synthesis. [3]

Why This Differs From Exogenous GH

Exogenous recombinant human GH suppresses endogenous pituitary function through negative feedback on somatostatin. CJC-1295 works upstream, preserving the feedback arc. IGF-1 levels still rise, but the pulsatile pattern that governs receptor sensitivity is maintained. The 2006 Journal of Clinical Endocrinology and Metabolism Phase II trial by Teichman et al. Demonstrated that a single 2 mg/kg dose of CJC-1295 DAC sustained elevated GH secretion for up to 14 days without abolishing pulsatility. [1]

The Evidence Base: What Trials Actually Show

No randomised controlled trial has enrolled competitive powerlifters or strength athletes to study CJC-1295. The evidence hierarchy here is: Phase I/II human PK/PD data, mechanistic cell and animal studies on GH/IGF-1 and musculoskeletal tissue, and structured practitioner-experience reports. Consumers should weigh claims accordingly.

Phase I/II Human Pharmacokinetic Data

Teichman et al. (2006) conducted a double-blind, placebo-controlled, dose-escalation trial (N=65 healthy adults) testing CJC-1295 DAC at 30, 60, 90, and 120 mcg/kg. Mean IGF-1 concentrations rose 28 to 43% above baseline across all active dose groups and remained elevated for 14 to 21 days post-injection. [1] GH pulse amplitude increased without loss of pulsatility. Adverse events were mild: transient facial flushing in 7 of 47 treated subjects, and no clinically significant changes in fasting glucose at any dose studied.

A separate Phase I study published via ClinicalTrials.gov (NCT00121966) examined single-dose pharmacokinetics in 21 healthy volunteers. Plasma half-life for CJC-1295 DAC was confirmed at 5.8 to 8.1 days. [4] This extended half-life is the pharmacological rationale for twice-weekly dosing in clinical and off-label settings.

IGF-1, Collagen, and Tendon Repair

IGF-1 receptor signalling in tendon fibroblasts increases collagen type I mRNA expression by approximately 2-fold in vitro, according to data published in the Journal of Applied Physiology. [5] In rodent Achilles tendon injury models, local IGF-1 administration accelerated histological repair scores by 40% at four weeks compared with saline controls. [6] These are animal data; translation to human powerlifters is plausible but not confirmed by RCT.

Muscle Protein Synthesis

GH alone is a weak direct stimulus to skeletal muscle protein synthesis. The effect is largely indirect, mediated through hepatic and local muscle IGF-1 production. A Cochrane review of GH administration in healthy adults found statistically significant increases in lean body mass (mean difference +1.6 kg, 95% CI 0.8 to 2.4 kg) but no consistent improvement in muscle strength measured by dynamometry. [7] Powerlifters should not expect CJC-1295 to replace progressive overload or caloric periodisation for strength gain.

Sleep Quality and Recovery

A study in the Journal of Clinical Sleep Medicine found that slow-wave sleep duration correlates (r=0.61) with overnight GH pulse amplitude in healthy men aged 18 to 45. [8] By amplifying each pulse, CJC-1295 may extend the anabolic window during sleep. However, no published trial has measured sleep architecture as a primary outcome in CJC-1295-treated subjects.

Structured Powerlifting Protocol

This protocol is a clinical decision framework developed by the HealthRX medical team for board-certified physician review before individual prescription. It integrates published PK/PD data, mechanistic evidence, and structured practitioner reporting. It is not a self-administration guide.

Compound Selection: DAC vs. No-DAC

For powerlifters prioritising simplicity and consistent IGF-1 elevation, CJC-1295 with DAC is preferred. The extended half-life means two injections per week maintain near-steady-state receptor occupancy. CJC-1295 without DAC (sometimes called Modified GRF 1-29 or Mod GRF) has a plasma half-life of 15 to 30 minutes and requires injection within minutes before sleep to hit the endogenous GH pulse, or pairing with a GH secretagogue like ipamorelin for a synergistic dual-receptor stimulus. [9]

Dosing Schedule

CJC-1295 with DAC (preferred for powerlifting cycles):

• Dose: 100 to 300 mcg per injection, subcutaneous
• Frequency: 2x per week (e.g., Monday and Thursday)
• Injection site: lower abdomen, 2 cm lateral to navel, rotating sites
• Cycle length: 12 to 16 weeks
• Off-period: minimum 4 to 8 weeks before re-starting to allow IGF-1 to return to baseline

CJC-1295 without DAC combined with ipamorelin (for those preferring pulsatile dosing):

• CJC-1295 no-DAC: 100 mcg per injection
• Ipamorelin: 200 to 300 mcg per injection, same syringe
• Frequency: once nightly, 30 to 60 minutes before sleep
• Cycle length: 12 to 16 weeks

The combination approach targets two complementary receptor systems simultaneously. CJC-1295 without DAC activates the GHRH receptor; ipamorelin activates the ghrelin/GHS-R1a receptor. Published receptor pharmacology shows additive GH release when both pathways are stimulated concurrently. [9]

Timing Around Training

For twice-weekly DAC dosing, injection day does not need to align with training days. Steady-state pharmacokinetics make acute peri-workout timing irrelevant. For nightly no-DAC plus ipamorelin, inject after the last meal of the day (insulin suppresses GH release; waiting 2 to 3 hours post-meal optimises the nocturnal GH pulse). [10]

Concurrent Nutrition Considerations

GH is anabolic but also lipolytic. A caloric surplus of 200 to 300 kcal above total daily energy expenditure, with protein at 2.0 to 2.4 g/kg bodyweight, matches the anabolic environment that maximises IGF-1-driven connective-tissue synthesis. A 2017 analysis in the American Journal of Clinical Nutrition confirmed that dietary protein at or above 1.6 g/kg/day is the minimum threshold for positive nitrogen balance in resistance-trained adults, with diminishing returns above 2.2 g/kg/day. [11]

Monitoring Labs and Safety Endpoints

Baseline Labs (Before Starting)

Order at baseline and again at week 8 of the cycle:

• IGF-1 (serum, morning draw)
• Fasting glucose and insulin
• HbA1c
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid panel (TSH, free T4), GH can unmask subclinical hypothyroidism
• Testosterone and LH/FSH (to establish baseline in male athletes)
• Complete metabolic panel

IGF-1 Target Range

The goal is to raise IGF-1 into the upper quartile of the age-matched reference range, not above the upper limit of normal. The Endocrine Society's 2011 clinical practice guideline on acromegaly defines IGF-1 above the age- and sex-adjusted upper limit of normal as biochemically abnormal. [12] Supraphysiologic IGF-1 is associated with increased colorectal cancer risk in epidemiological cohorts. [13] Keeping IGF-1 within the normal reference interval reduces this risk signal.

Glucose Monitoring

GH exerts anti-insulin effects at the receptor level, reducing glucose uptake in skeletal muscle and adipose tissue. In the Teichman et al. Trial, no subjects developed frank hyperglycaemia, but the study duration was short. Powerlifters with pre-diabetes (HbA1c 5.7 to 6.4%) should be monitored monthly. Those with HbA1c of 6.4% or above should not use GH-secreting peptides without direct endocrinologist supervision. [1] [14]

Thyroid Function

Elevated GH can increase peripheral conversion of T4 to T3, occasionally unmasking subclinical hypothyroidism. A TSH check at week 8 is standard in any GH-stimulating protocol. The American Thyroid Association recommends TSH reference range 0.4 to 4.0 mIU/L as the normal interval. [15]

Expected Timeline of Outcomes for Powerlifters

Outcomes follow a predictable sequence based on the biology of each tissue type.

Weeks 1 to 4: Sleep and Recovery

Most users report improved sleep quality and subjective recovery within the first two to three weeks. This likely reflects the amplification of slow-wave sleep GH pulses. Objective soreness scores and session-to-session readiness ratings may improve before any structural tissue change is detectable. [8]

Weeks 4 to 8: Connective Tissue Symptom Relief

Tendon and joint discomfort from high-frequency maximal loading typically begins to ease in this window. Collagen synthesis rates in human patellar tendon peak 24 to 72 hours post-load and are IGF-1-sensitive, so cumulative benefit builds over repeated weekly cycles. [5] Subjective joint comfort scores in practitioner case series improve 30 to 50% by week 8, though no placebo-controlled trial in powerlifters has confirmed this figure.

Weeks 8 to 16: Body Composition Shifts

Lean mass accretion and mild fat reduction become measurable via DEXA in weeks 8 to 16. The Cochrane review cited above found mean lean mass increases of 1.6 kg over GH-stimulating interventions of 12 to 24 weeks. [7] For a 100 kg powerlifter, this represents a modest but meaningful compositional shift in favour of muscle over fat.

Post-Cycle: IGF-1 Washout

After stopping CJC-1295 DAC, IGF-1 returns to pre-treatment baseline within 28 to 35 days based on the half-life kinetics reported by Teichman et al. [1] A post-cycle IGF-1 draw at week 4 off-cycle confirms return to baseline and clears the athlete to repeat the cycle.

Side Effect Profile and Contraindications

Common Adverse Effects

Transient facial flushing occurs in roughly 15% of users in the first 30 to 60 minutes post-injection and resolves without treatment. Water retention of 1 to 3 kg is common in the first two weeks due to GH-driven renal sodium retention; it typically self-resolves. [1] Injection-site erythema or mild induration occurs with subcutaneous administration and usually indicates need for site rotation rather than discontinuation.

Contraindications

Do not use CJC-1295 in the following situations:

• Active malignancy or personal history of cancer (IGF-1 is mitogenic) [13]
• Uncontrolled diabetes mellitus (HbA1c above 8%)
• Pregnancy or lactation
• Pituitary adenoma or active pituitary disease
• Hypersensitivity to synthetic peptide excipients
• Age below 25 years (the GH axis is physiologically active; amplification is unnecessary and theoretical risk of epiphyseal effects exists) [16]

Drug Interactions

Glucocorticoids attenuate GH secretory responses to GHRH; powerlifters using therapeutic corticosteroids for injury management should expect blunted CJC-1295 response. [17] Insulin co-administration requires careful glucose monitoring because both GH-induced insulin resistance and exogenous insulin are in play simultaneously.

Stacking Considerations: What Pairs With CJC-1295 in Strength Protocols

Ipamorelin

Ipamorelin is the most evidence-supported co-agonist. It selects for GHS-R1a without meaningfully raising cortisol or prolactin, unlike older GH secretagogues such as GHRP-2 or GHRP-6. The dual GHRH plus ghrelin-receptor stimulation produces additive GH release in rodent and human pharmacology studies. [9] Typical practitioner protocol: 200 to 300 mcg ipamorelin with 100 mcg CJC-1295 no-DAC, injected nightly.

BPC-157

Body protection compound 157 is a 15-amino-acid peptide studied for its effects on tendon, ligament, and muscle healing. A 2019 review in the Journal of Physiology and Pharmacology summarised animal data showing accelerated Achilles tendon repair and gastric mucosal protection. [18] Human RCT data are absent. Powerlifters with acute tendon injuries sometimes layer BPC-157 (200 to 500 mcg daily) onto a CJC-1295 background. The theoretical rationale is complementary repair pathways (local vs. Systemic), but no trial has tested the combination.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 modulates actin polymerisation and has shown anti-inflammatory and repair-promoting effects in cardiac and skeletal muscle injury models. [19] Like BPC-157, human evidence is limited to case reports and early-phase data. Stacking with CJC-1295 is practitioner-driven and not supported by comparative RCT data.

Regulatory Status and Compounding Considerations

CJC-1295 is not FDA-approved as a drug product for any indication. It was investigated as a clinical compound by ConjuChem Biotechnologies and reached Phase II trials before development was discontinued. [1] In the United States, it may be compounded by 503A compounding pharmacies for specific patient prescriptions under physician supervision, though FDA guidance from 2023 placed several peptides including CJC-1295 on a list of substances under review for inclusion in Category 2 (substances that may not be compounded). [20] Athletes should confirm current regulatory status with their prescribing physician.

The World Anti-Doping Agency (WADA) Prohibited List classifies GH-releasing peptides, including GHRH analogues, as prohibited in- and out-of-competition under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Competitive powerlifters subject to WADA-compliant drug testing face disqualification if CJC-1295 or its metabolites are detected. [21]

Physician Monitoring Checklist

A summary of the clinical touchpoints a prescribing physician should schedule:

• Baseline (week 0): Full labs as listed above, body weight, DEXA if available, document tendon/joint symptom scores
• Week 4: Fasting glucose, body weight, symptom review
• Week 8: Full repeat labs (IGF-1, metabolic panel, thyroid), dose adjustment if IGF-1 is outside target range
• Week 12 to 16 (end of cycle): Final labs, DEXA, symptom re-scoring
• Week 20 (4 weeks post-cycle): IGF-1 to confirm washout, fasting glucose

The Endocrine Society recommends that any intervention targeting the GH axis be managed by a physician familiar with IGF-1 interpretation and the differential diagnosis of acromegaly. [12] IGF-1 above the age-adjusted upper limit of normal on two separate draws warrants cessation of the peptide and endocrinology referral.